Loading cancer entity…
Loading cancer entity…
Clinical trials
8,119 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,288)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05288062 | Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma | terminated | Phase 2 | 17 | Mayo ClinicOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT01947140 | Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies(PDX+Romi) | terminated | Phase 1 / Phase 2 | 57 | Jennifer AmengualOTHER | 1 | Sep 16, 2026 |
| NCT04649073 | Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 11 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06622226 | A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | terminated | Phase 1 | 2 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 29, 2026 | clinicaltrials |
| NCT03598608 | Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) | terminated | Phase 1 / Phase 2 | 137 | Merck Sharp & Dohme LLCINDUSTRY | 6 | Jul 28, 2026 | clinicaltrials |
| NCT02967276 | Clinical Activity of Metformin With High-dose of Dexamethasone in Relapse Multiple Myeloma(METDEXA-MM) | terminated | Phase 2 | 28 | University of Campinas, BrazilOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06028373 | A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas | terminated | Phase 1 | 38 | Antengene Biologics LimitedINDUSTRY | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05828589 | A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies | terminated | Phase 1 | 51 | BeOne MedicinesINDUSTRY | 4 | Jul 14, 2026 | clinicaltrials |
| NCT06470451 | Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL(FLASH2) | terminated | Phase 3 | 70 | SoligenixINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT04318327 | BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma | terminated | Phase 1 | 96 | Novartis PharmaceuticalsINDUSTRY | 4 | Jul 9, 2026 | clinicaltrials |
| NCT04855136 | Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma(KarMMa-7) | terminated | Phase 1 | 21 | CelgeneINDUSTRY | 2 | Jul 9, 2026 | clinicaltrials |
| NCT06120504 | A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers | terminated | Phase 1 | 22 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 2 | Jul 6, 2026 | clinicaltrials |
| NCT05660967 | Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma(EPCORE DLBCL-3) | terminated | Phase 2 | 111 | GenmabINDUSTRY | 12 | Jul 2, 2026 | clinicaltrials |
| NCT05255601 | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma(RELATIVITY-069) | terminated | Phase 1 / Phase 2 | 5 | Bristol-Myers SquibbINDUSTRY | 7 | Jun 26, 2026 | clinicaltrials |
| NCT05498545 | Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 | 8 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT05453396 | Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies | terminated | Phase 2 | 11 | University of WashingtonOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05025423 | Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma | terminated | Phase 2 | 7 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT05824689 | Fluoroquinolone Resistance Prevalence Study(FRE) | terminated | — | 124 | Hackensack Meridian HealthOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT04758650 | Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis(MITRAS) | terminated | Phase 2 | 29 | Universitair Ziekenhuis BrusselOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05515406 | A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL | terminated | Phase 1 | 9 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT03946332 | Physical Activity for Myeloma Autograft Longitudinal Study(PAMAL) | terminated | N/A | 60 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT01421927 | Lenalidomide After Reduced-intensity Allogeneic Stem Cell Transplantation for Relapsed Multiple Myeloma(REVALLO) | terminated | Phase 1 | 13 | University Hospital, BordeauxOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT01962636 | Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases | terminated | N/A | 200 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04824794 | GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies | terminated | Phase 1 / Phase 2 | 130 | GenmabINDUSTRY | 20 | May 19, 2026 | clinicaltrials |
| NCT03246906 | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation | terminated | Phase 2 | 150 | Fred Hutchinson Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT03757221 | Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple Myeloma(IDARA) | terminated | Phase 2 | 55 | University Hospital, CaenOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06870487 | A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers | terminated | Phase 1 | 6 | PfizerINDUSTRY | 2 | May 8, 2026 | clinicaltrials |
| NCT04331119 | Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas | terminated | Phase 2 | 17 | Washington University School of MedicineOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05050461 | Immune Response After SARS-CoV-2 (COVID-19) Vaccination in a Context of Non-Hodgkin Lymphoma(LYMPHO-CoVac) | terminated | N/A | 120 | Versailles HospitalOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05896163 | A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.(MAPtivate-6) | terminated | Phase 1 / Phase 2 | 40 | PfizerINDUSTRY | 4 | May 6, 2026 | clinicaltrials |
| NCT03506373 | Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia | terminated | Phase 2 | 21 | Mayo ClinicOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03173092 | A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM) | terminated | Phase 4 | 141 | TakedaINDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT06125028 | [68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma(LYMFOR) | terminated | Phase 3 | 8 | Pentixapharm AGINDUSTRY | 5 | Apr 28, 2026 | clinicaltrials |
| NCT03622775 | Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant | terminated | Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05090566 | MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma | terminated | Phase 2 | 46 | PfizerINDUSTRY | 2 | Apr 24, 2026 | clinicaltrials |
| NCT06163898 | A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma | terminated | Phase 1 | 4 | CelgeneINDUSTRY | 2 | Apr 21, 2026 | clinicaltrials |
| NCT05605119 | First in Human, Dose Escalation, Dose Expansion Study of AUR105(SURYA-1) | terminated | Phase 1 | 17 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05607199 | A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics(BHARAT-1) | terminated | Phase 1 | 27 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05983965 | Study of Tazemetostat in Lymphoid Malignancies | terminated | Phase 1 | 6 | University of Alabama at BirminghamOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05498220 | Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma | terminated | Phase 2 | 5 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06088654 | Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 23 | Innate PharmaINDUSTRY | 3 | Apr 14, 2026 | clinicaltrials |
| NCT01081028 | Connect® MM- The Multiple Myeloma Disease Registry | terminated | — | 3,011 | CelgeneINDUSTRY | 2 | Apr 13, 2026 | clinicaltrials |
| NCT04853329 | Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma | terminated | Phase 1 | 7 | Conjupro Biotherapeutics, Inc.INDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
| NCT02681302 | Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence(CPIT001) | terminated | Phase 1 / Phase 2 | 46 | Hackensack Meridian HealthOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT05618366 | Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma | terminated | Phase 1 | 3 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT04903197 | Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma | terminated | Phase 1 | 18 | Novartis PharmaceuticalsINDUSTRY | 7 | Apr 1, 2026 | clinicaltrials |
| NCT01453088 | Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older | terminated | Phase 2 | 63 | Hackensack Meridian HealthOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT03547115 | A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML | terminated | Phase 1 | 84 | MEI Pharma, Inc.INDUSTRY | 1 | Mar 17, 2026 | clinicaltrials |
Data updated 21 hours agoSource updated Sep 28, 2026source: clinicaltrials